This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| doxorubicin | |
|---|---|
| Drug name | Doxorubicin |
| Caption | Chemical structure of doxorubicin |
| Tradename | Adriamycin |
| Routes of administration | Intravenous, liposomal formulations |
| Class | Anthracycline antibiotic, antineoplastic |
| Legal status | Prescription-only |
doxorubicin is an anthracycline antineoplastic agent widely used in the treatment of multiple malignancies. Developed in the mid-20th century, it is a core component of combination regimens for solid tumors and hematologic cancers. Its clinical use balances potent cytotoxic efficacy against dose-limiting cardiotoxicity, prompting development of alternative formulations and cardioprotective strategies.
Doxorubicin is indicated for treatment of Hodgkin lymphoma, non-Hodgkin lymphoma, acute myeloid leukemia, acute lymphoblastic leukemia, breast cancer, ovarian cancer, soft tissue sarcoma, osteosarcoma, Ewing sarcoma, Wilms tumor, and as part of multiagent regimens for multiple myeloma, small cell lung cancer, non-small cell lung cancer, and retinoblastoma. It is routinely combined with agents such as cyclophosphamide, vincristine, prednisone, dacarbazine, cisplatin, and bleomycin in protocols influenced by treatment paradigms developed at institutions like Memorial Sloan Kettering Cancer Center, MD Anderson Cancer Center, and Dana-Farber Cancer Institute. In pediatric oncology, doxorubicin features in protocols established through cooperative groups including the Children's Oncology Group and the European Society for Paediatric Oncology.
Doxorubicin intercalates into DNA, inhibiting macromolecular biosynthesis, and stabilizes topoisomerase II cleavage complexes, causing DNA double-strand breaks; these actions were elucidated alongside studies by researchers connected to National Cancer Institute, Albert Einstein College of Medicine, and laboratories influenced by work from Paul Ehrlich-era chemotherapy pioneers. It generates reactive oxygen species via redox cycling in mitochondria, a mechanism linked to mitochondrial dysfunction observed in preclinical studies at Harvard Medical School, Stanford University School of Medicine, and Johns Hopkins School of Medicine. The drug’s interaction with nuclear and mitochondrial topoisomerase II isoforms explains both antitumor activity and off-target toxicity, a subject addressed in reports from the American Association for Cancer Research and European Society for Medical Oncology meetings.
After intravenous administration, doxorubicin distributes widely to tissues with high affinity for cardiac and hepatic tissues, a distribution profile characterized in pharmacokinetic analyses by groups at Food and Drug Administration and pharmacology units at University College London. Hepatic metabolism via reduction and conjugation, biliary excretion, and enterohepatic recirculation determine clearance, considerations integrated into dosing adjustments recommended by regulatory authorities such as the European Medicines Agency and the U.S. Food and Drug Administration. Plasma half-life is multi-phasic; population PK models published by investigators at Mayo Clinic, Cleveland Clinic, and Vanderbilt University Medical Center inform therapeutic monitoring and scheduling. Liposomal encapsulation and pegylation alter volume of distribution and clearance, as shown in trials coordinated by groups at Institut Gustave Roussy and Royal Marsden Hospital.
Dose-dependent cardiomyopathy and congestive heart failure are principal toxicities, first reported in clinical series from centers including Memorial Sloan Kettering Cancer Center and Massachusetts General Hospital; cumulative lifetime dose limits derive from multicenter analyses by National Institutes of Health investigators. Myelosuppression, mucositis, alopecia, and nausea occur commonly and are managed according to guidance from American Society of Clinical Oncology and European Society for Medical Oncology. Secondary leukemias linked to topoisomerase II inhibition have been described in cohorts tracked by the Surveillance, Epidemiology, and End Results Program and cooperative oncology groups. Cardiotoxicity risk mitigation strategies include baseline and serial imaging programs recommended by societies such as the American Heart Association and the European Society of Cardiology, and use of cardioprotectants like dexrazoxane informed by studies from Stanford University and University of Pennsylvania.
Conventional formulation is administered intravenously, often via infusion protocols developed at chemotherapy centers including Royal Marsden Hospital and MD Anderson Cancer Center. Liposomal and pegylated liposomal formulations were developed to reduce cardiotoxicity and improve tumor targeting; pivotal trials conducted by teams at Institut Curie, Memorial Sloan Kettering Cancer Center, and pharmaceutical companies led to approvals reviewed by U.S. Food and Drug Administration and European Medicines Agency. Regional delivery techniques—intraperitoneal, intra-arterial, and intravesical—have been investigated in studies at Mayo Clinic, Cleveland Clinic, and Johns Hopkins Hospital. Dose modification algorithms for hepatic impairment and drug interactions involve specialists from Royal Free Hospital and pharmacology groups at University of Cambridge.
Doxorubicin emerged from natural product screening of actinomycetes isolated in the 1950s, with discovery work reported by researchers at Farmitalia Research Laboratories and collaborations involving University of Naples Federico II. Early clinical development in the 1960s and 1970s involved trials at Memorial Sloan Kettering Cancer Center, MD Anderson Cancer Center, and European centers like Institut Gustave Roussy. Its commercial development under trade names such as Adriamycin was steered by pharmaceutical firms and regulatory reviews by Food and Drug Administration panels. Historical analyses link its emergence to the broader antibiotic-derived chemotherapy era inaugurated by discoveries associated with Selman Waksman and contemporaneous oncology program growth at institutions including NCI.
Ongoing research aims to reduce cardiotoxicity, improve tumor selectivity, and overcome resistance. Strategies include antibody-drug conjugates and nanoparticle carriers developed at Dana-Farber Cancer Institute, National Cancer Institute, and industrial partners such as Roche and Pfizer. Biomarker-driven dosing and genomics-informed susceptibility studies draw on consortia including The Cancer Genome Atlas and International Cancer Genome Consortium. Preclinical and clinical trials exploring combination regimens with targeted agents from groups at Memorial Sloan Kettering Cancer Center, Massachusetts General Hospital Cancer Center, and Johns Hopkins Kimmel Cancer Center continue to refine utility. Research into cardioprotective interventions involves collaborations across American Heart Association, European Society of Cardiology, and translational teams at Stanford University School of Medicine and University of Oxford.
Category:Antineoplastic drugs